13 November 2020: Original Paper
Single-Center Retrospective Analysis of Prophylaxis and Treatment of Pneumonia in Patients with Renal Dysfunction After Renal Transplantation
Jianyong Pan C , Yingxin Fu A* , Yu Cao C , Gang Feng F , Jie Zhao D , Xiaofeng Shi D , Chunbai Mo A , Wenli Song F , Zhongyang Shen AG*DOI: 10.12659/AOT.925126
Ann Transplant 2020; 25:e925126
Table 3 Comparison of the onset and treatment characteristics of PCP among 2 groups.
| ARF (n = 37) | NRF (n = 31) | P value | |
|---|---|---|---|
| Onset (months) | 5.9 (4–8.7) | 5.4 (2.7–10.4) | 0.218 |
| TMP-SMX prophylaxis | 15 (40.5%) | 2 (6.5%) | 0.047 |
| PCP symptom | |||
| Fever | 30 (81.1%) | 27 (87.1%) | 0.734 |
| Cough | 14 (37.8%) | 9 (29%) | 0.445 |
| Suffocation | 18 (48.6%) | 10 (32.3%) | 0.171 |
| Weakness | 3 (8.1%) | 0 | 0.304 |
| Diarrhea | 1 (2.7%) | 0 | >0.05 |
| CMV(+) | 16 (43.2%) | 12 (38.7%) | 0.705 |
| Neutrophil granulocyte(10/L) | 6.5 (4.8–8.5) | 6.9 (5.4–8.5) | 0.487 |
| Lymphocyte count(10/L) | 0.6 (0.5–0.9) | 1.1 (0.7–1.6) | |
| BG detection(+) | 18 (48.6%) | 8 (25.8%) | 0.054 |
| PMD | 20 (54.1%) | 16 (51.6%) | 0.841 |
| Anti-PCP Steroid usage | 21 (56.8%) | 16 (51.6%) | 0.671 |
| Anti PCP TMP-SMX dose(g) | 6 (4.3–6) | 6 (3–6) | 0.482 |
| Caspofungin | 25 (67.6%) | 18 (58.1%) | 0.418 |
| BG detection – serum 1-3-(Beta-D) Glucan concentration; PMD – pathogenic microbiological diagnosis; ARF – abnormal renal function group; NRF – normal renal function. | |||